Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New […]
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced […]
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]
…..to Commercialize Efgartigimod Across Europe and Israel Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in […]
Copyright © 2022 | WordPress Theme by MH Themes
